Welcome to a 4-part series exploring a question that the entire cell and gene therapy community is struggling with at the moment:
“Where will tomorrow’s workforce come from?”
The cell and gene therapy field has been advancing at a breakneck speed for the best part of a decade, fuelled by long-awaited clinical successes, commercial breakthroughs, and a related startling increase in activity from both investors and big pharma. But with this relentless pace of growth and innovation comes the fundamental challenge of developing a sufficiently large and skilled workforce to support and maintain the sector.
In this first episode of the series, we will frame the scale and nature of the issue through the eyes of cell and gene therapy leaders including Sven Kili, James Miskin, Michael Lehmicke, Qasim Rafiq, Emily Hopewell, Frank Barry and Parviz Shamlou.